Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112

• Status: Completed
• Trial end date: 2020-07-16
• Target enrollment: 0
• Participant gender: All

Summary

A phase I clinical trial to evaluate the pharmacokinetic interactions and safety between AD-2111 and AD-2112

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Addpharma Inc.

Criteria

Inclusion Criteria:

• Healthy Adult aged 19 and more at the time of screening visit

• Body mass index (BMI) between 18.5 kg/m2 and 27.0 kg/m2 at the time of screening visit

Exclusion Criteria:

• As a result of laboratory tests, the following figures: ALT or AST or total bilirubin > 1.5 times upper limit of normal range

• As a result of laboratory tests, the following figures: Creatinine clearance < 80mL/min